secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095419
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway
--------------------------------------------------------------------------------

- Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.
- R&D expenses $28.9M in Q2 2024 vs $18.8M Q2 2023, up $10.2M on pipeline advancement.
- G&A expenses $7.1M in Q2 2024 vs $6.2M Q2 2023, up $0.9M on higher personnel costs.
- ORIC-114 Phase 1b dose escalation complete; expansion cohorts in EGFR/HER2 mutant NSCLC dosed; data expected H1 2025.
- ORIC-944 combo dosing initiated with NUBEQA and ERLEADA; clinical trial agreements with Bayer and J&J.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/0000950170-24-095419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024095419/oric-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer